VINORELBINE INJECTION, USP SOLUTION

Country: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

VINORELBINE (VINORELBINE TARTRATE)

থেকে পাওয়া:

FRESENIUS KABI CANADA LTD

এটিসি কোড:

L01CA04

INN (International Name):

VINORELBINE

ডোজ:

10MG

ফার্মাসিউটিকাল ফর্ম:

SOLUTION

রচনা:

VINORELBINE (VINORELBINE TARTRATE) 10MG

প্রশাসন রুট:

INTRAVENOUS

প্যাকেজ ইউনিট:

15G/50G

প্রেসক্রিপশন টাইপ:

Prescription

Therapeutic area:

ANTINEOPLASTIC AGENTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0126071001; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2021-01-25

পণ্য বৈশিষ্ট্য

Vinorelbine Injection, USP- Product Monograph
Page 1 of 35
PRODUCT MONOGRAPH
PR
VINORELBINE INJECTION, USP
Sterile Solution for Injection
10 mg vinorelbine (as vinorelbine tartrate) per mL
SOLUTION MUST BE DILUTED BEFORE USE
Antineoplastic Agent
FRESENIUS KABI CANADA LTD.
165 Galaxy Blvd, Suite 100
Toronto, ON M9W 0C8
Date of Revision:
August 14, 2023
Submission Control No: 273007
Vinorelbine Injection, USP- Product Monograph
Page 2 of 35
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................12
OVERDOSAGE
................................................................................................................14
ACTION AND CLINICAL PHARMACOLOGY
............................................................15
STORAGE AND STABILITY
..........................................................................................16
SPECIAL HANDLING INSTRUCTIONS
.......................................................................16
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................17
PART II: SCIENTIFIC INFORMATION
................................................................................18
PHARMACEUTICAL INFORMATION
...............................